Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.